MedTrace Logo

Goblet Cell Degranulation Produced by Intranasal Tear Neurostimulator (ITN) in Dry Eye Disease

NCT03827564 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 14

Last updated 2021-08-16

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to evaluate goblet cell degranulation following acute use of the Intranasal Tear Neurostimulator in participants with dry eye.

Conditions

  • Dry Eye Syndromes

Interventions

DEVICE

Intranasal Tear Neurostimulator (ITN) [TrueTear®]

The ITN applies a small electrical current to the nasal cavities to gently activate the body's natural tear production system.

Sponsors & Collaborators

  • Allergan

    lead INDUSTRY

Principal Investigators

  • Stephen Pflugfelder, MD · Baylor College of Medicine, Department of Ophthalmology

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
22 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-06-24
Primary Completion
2020-06-08
Completion
2020-06-08
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03827564 on ClinicalTrials.gov